Endovasc, Inc. develops, markets and licenses biopharmaceutical products, particularly liposomal drug delivery methods, for the human healthcare industry. The Company develops liposomes, which are microscopic cell-like spheres composed of a thin, durable lipid membrane surrounding a hollow compartment. Liposomes entrap and protect drugs from degradation in the blood stream and can be engineered to regulate the transport of molecules across their outer membrane. Using this technology, Endovasc is developing products that deliver drugs to their intended target and release them with efficiency and control. Its product development is focused on two core products: Liprostin and Angiogenix. The Company has not generated any revenues from the sale of these products and has historically operated with significant losses.